RESUMEN
BACKGROUND: Sleep disturbance in multiple sclerosis has received little research attention despite the potential influence it may have on disease impact. OBJECTIVE: To estimate the prevalence of sleep disorders in a large community sample of individuals with multiple sclerosis. METHODS: A cross-sectional self-report survey of 1063 persons with multiple sclerosis. Sleep was assessed using the Women's Health Initiative Insomnia Rating Scale and Medical Outcomes Study Sleep measure. RESULTS: The prevalence of sleep problems in multiple sclerosis is significantly higher than in the general population or other chronic diseases and may affect women with multiple sclerosis more than men. CONCLUSION: Sleep disturbance should routinely be evaluated in patients with multiple sclerosis and new interventions developed.
Asunto(s)
Esclerosis Múltiple/complicaciones , Trastornos del Sueño-Vigilia/epidemiología , Adulto , Enfermedad Crónica , Estudios Transversales , Femenino , Encuestas Epidemiológicas , Humanos , Masculino , Prevalencia , Trastornos del Sueño-Vigilia/etiología , Ronquido/epidemiología , Estados Unidos/epidemiología , Washingtón/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Recognizing the need for more evidence-based multiple sclerosis (MS) rehabilitation, in the mid-2000s several initiatives were undertaken to explore why there had been a paucity of such research and to determine strategies to reverse this pattern. EXPERT-OPINION-PAPER: In 2004 the National Multiple Sclerosis Society (NMSS) convened an expert opinion panel, reviewed evidence-based MS rehabilitation research, and published the paper on the web. It was concluded that much of the MS rehabilitation carried out was based on experience, with little research backing it up. INCREASING THE QUALITY AND QUANTITY OF MS REHABILITATION RESEARCH: Largely as a result of the conclusions of the Expert-Opinion-Paper, the NMSS convened a conference of a large number of MS and rehabilitation experts in New York in May, 2005. This conference made many recommendations of ways to increase the quantity and quality of MS research. STATE OF THE SCIENCE CONFERENCE: In September, 2006, a follow-up conference was held in Washington, D.C... This conference, primarily sponsored by the University of Washington Multiple Sclerosis Rehabilitation Research and Training Center (MS RRTC), focused on some of the under-studied "hidden" disabilities present in persons with MS. This paper discusses the details and recommendations of these latter two conferences.
Asunto(s)
Investigación Biomédica/normas , Investigación Biomédica/tendencias , Esclerosis Múltiple/rehabilitación , Investigación/normas , Investigación/tendencias , Medicina Basada en la Evidencia , HumanosRESUMEN
Depressive symptoms and disorders among individuals with multiple sclerosis (MS) are more common when compared to other chronic illnesses and the general population, but relatively little is known about the use of antidepressant medication in this population. In this cross-sectional study of 542 community-dwelling adults with MS, we examined the prevalence of antidepressant use and employed multivariate logistic regression modeling to identify factors significantly associated with antidepressant use. Thirty-five percent of the sample reported currently using at least one antidepressant medication. Gender, marital status, insurance status, fatigue, and use of disease modifying therapies were all significantly associated with antidepressant use. Just over half of the sample endorsed a clinically significant level of depressive symptoms, and the majority of this group was not currently taking an antidepressant. Conversely, 41% of those with depressive symptoms reported taking at least one antidepressant medication. More research is needed to better understand why people with MS and depressive symptoms use or do not use antidepressant medications and to further explore the possibility of an under-treatment of depressive disorder in this population. Rigorous studies testing the feasibility, acceptability, and efficacy of currently available therapies for depression in the MS population should also be conducted.
Asunto(s)
Antidepresivos/uso terapéutico , Estado de Salud , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/psicología , Anciano , Estudios Transversales , Escolaridad , Empleo , Femenino , Encuestas Epidemiológicas , Humanos , Seguro de Salud , Masculino , Medicare , Persona de Mediana Edad , Sociedades Médicas , Estados Unidos , WashingtónRESUMEN
Determining multiple sclerosis (MS) clinical course is important in research and clinical practice. However, many patients do not know their clinical course, limiting the option to use self-report in research studies including surveys. In order to address this, we developed a self-report item to be used in self-administered mailed surveys displaying graphically the courses of MS. The validity of this item was then evaluated by comparing physician-assessed disease clinical course to patient response on the self-report item on 94 of 99 consecutive patients seen in an MS specialty clinic. Kappa statistics were calculated comparing self-assessed versus physician-assessed MS clinical course for the four common MS clinical courses (kappa=0.45) and for relapsing remitting versus other courses (kappa=0.62) indicating substantial agreement. Subsequent administration of the item by mail to 1371 individuals with MS in Washington and Montana determined that while most individuals responded as intended to the item, persons with less than a high school education (P=0.009) or over the age of 60 ( P = 0.002) were significantly more likely to leave the item blank. It appears that this item may be used to obtain a rough estimate of MS clinical course in research using self-report surveys where physician assessments are impractical.